Jukka Westerbacka

1. MENEGHINI, Luigi F., MAURICIO, Didac, ORSI, Emanuela, LALIĆ, Nebojsa M., CALI, Anna M. G., WESTERBACKA, Jukka, STELLA, Peter, CANDELAS, Cristophe, PILORGET, Valerie, PERFETTI, Riccardo, et al., URBANČIČ-ROVAN, Vilma (sodelavec pri raziskavi), FERJAN, Simona (sodelavec pri raziskavi), RAVNIK-OBLAK, Maja (sodelavec pri raziskavi), et al. The Diabetes Unmet Need with Basal Insulin Evaluation (DUNE) study in type 2 diabetes : achieving HbA1c targets with basal insulin in a real-world setting. Diabetes, obesity and metabolism. 2019, vol. 21, iss. 6, str. 1492-1436. ISSN 1462-8902. DOI: 10.1111/dom.13673. [COBISS.SI-ID 5955500]

2. BATTELINO, Tadej, DANNE, Thomas, EDELMAN, Scymour, CHOUDHARY, P., RENARD, Eric, WESTERBACKA, Jukka, MUKHERJEE, Bhaswati, PICARD, Philippe, PILORGET, Valerie, BERGENSTAL, Richard. Comparison of second-generation basal insulin analogues glargine 300 u/ml and degludec 100 u/ml using continuous glucose monitoring in people with T1D : inrange randomised controlled trial. Diabetes technology & therapeutics. 2022, vol. 24, iss. s2, str. a-4. ISSN 1557-8593. https://www.liebertpub.com/doi/10.1089/dia.2022.2527.abstracts, DOI: 10.1089/dia.2022.2527.abstracts. [COBISS.SI-ID 150672643]

3. BATTELINO, Tadej, DANNE, Thomas, EDELMAN, Steve, CHOUDHARY, Pratik, RENARD, Eric, WESTERBACKA, Jukka, et al. Comparison of the basal insulin analogues Gla-300 and IDeg 100 using continuous glucose monitoring in people with type 1 diabetes: the InRange randomised controlled trial : invited lecture at the EASD 2022, 58th Annual Meeting, 19-23 September 2022. [COBISS.SI-ID 135521795]

4. BATTELINO, Tadej (avtor, korespondenčni avtor), DANNE, Thomas, EDELMAN, Steve, CHOUDHARY, Pratik, RENARD, Eric, WESTERBACKA, Jukka, MUKHERJEE, Bhaswati, PILORGET, Valerie, COUDERT, Mathieu, BERGENSTAL, Richard. Continuous glucose monitoring-based time-in-range usinginsulin glargine 300 units/ml versus insulin degludec100 units/ml in type 1 diabetes : the head-to-head randomizedcontrolled InRange trial. Diabetes, obesity & metabolism. 2023, vol. 25, iss. 2, [article no.] 14898, 545-555 str., ilustr. ISSN 1463-1326. https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.14898, Repozitorij Univerze v Ljubljani – RUL, DiRROS - Digitalni repozitorij raziskovalnih organizacij Slovenije, DOI: 10.1111/dom.14898. [COBISS.SI-ID 143145987]
projekt: P3-0343; financer: Slovenian Research Agency
projekt: DK108611; financer: National Institute of Diabetes and Digestive and Kidney Diseases (National Institute of Health)
projekt: Sofinancerji: Novo Nordisk, Sanofi, Eli Lilly, Boehringer Ingelheim, Indigo and Medtronic, AstraZeneca, Pfizer, Dxcom, Abbott and Roche, Abbott Diabetes Care, Sandoz, Novartis and Zealand Pharma